Spiden provides and develops products that enable real-time and continuous monitoring of blood biomarkers.
Lion (Spiden) has raised €38M across 2 funding rounds from 9 investors, most recently a Series A round in Dec 2024. Based in Freienbach, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-12-06 | Series A | €24M | — | View deal → |
| 2021-04-29 | Other | €15M | B-to-V Partners,Business Angels,Daniel Gutenberg,Edward Ludwig,Geberit,Kirill Evstratov+3 more | View deal → |
